GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RP Bio lnc (XKRX:314140) » Definitions » Debt-to-EBITDA

RP Bio lnc (XKRX:314140) Debt-to-EBITDA : 5.15 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is RP Bio lnc Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

RP Bio lnc's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩26,007 Mil. RP Bio lnc's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩4,774 Mil. RP Bio lnc's annualized EBITDA for the quarter that ended in Dec. 2023 was ₩5,977 Mil. RP Bio lnc's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 5.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RP Bio lnc's Debt-to-EBITDA or its related term are showing as below:

XKRX:314140' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.28   Med: 3.98   Max: 6.18
Current: 2.28

During the past 4 years, the highest Debt-to-EBITDA Ratio of RP Bio lnc was 6.18. The lowest was 2.28. And the median was 3.98.

XKRX:314140's Debt-to-EBITDA is ranked worse than
57.56% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs XKRX:314140: 2.28

RP Bio lnc Debt-to-EBITDA Historical Data

The historical data trend for RP Bio lnc's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RP Bio lnc Debt-to-EBITDA Chart

RP Bio lnc Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
6.18 4.11 3.85 3.12

RP Bio lnc Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.86 3.85 1.94 1.66 5.15

Competitive Comparison of RP Bio lnc's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, RP Bio lnc's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RP Bio lnc's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RP Bio lnc's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RP Bio lnc's Debt-to-EBITDA falls into.



RP Bio lnc Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RP Bio lnc's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(35549.916 + 2634.805) / 12255.228
=3.12

RP Bio lnc's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(26006.961 + 4774.218) / 5976.804
=5.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


RP Bio lnc  (XKRX:314140) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


RP Bio lnc Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RP Bio lnc's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RP Bio lnc (XKRX:314140) Business Description

Traded in Other Exchanges
N/A
Address
634, Samseong-ro, Gangnam-gu, Seoul, KOR, 06084
RP Bio lnc is engaged in the pharmaceutical manufacturing business. It produces softgels, finished drugs, and other products.

RP Bio lnc (XKRX:314140) Headlines

No Headlines